Karyopharm Therapeutics Inc (KPTI) Given Average Rating of “Hold” by Brokerages
Karyopharm Therapeutics Inc (NASDAQ:KPTI) has received an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $17.88.
A number of research firms have recently weighed in on KPTI. Wedbush reduced their target price on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, February 25th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Thursday, January 10th. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. ValuEngine raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. cut shares of Karyopharm Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $21.00 to $7.00 in a research note on Friday, March 1st.
Shares of Karyopharm Therapeutics stock traded up $0.13 during trading hours on Tuesday, reaching $4.98. The company’s stock had a trading volume of 794,297 shares, compared to its average volume of 1,501,281. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $21.71. The company has a quick ratio of 7.13, a current ratio of 7.13 and a debt-to-equity ratio of 0.56. The company has a market cap of $297.63 million, a PE ratio of -1.59 and a beta of 3.24.
In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 1,481,643 shares of the business’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total value of $7,126,702.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.26% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in KPTI. Ridgeback Capital Investments L.P. purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $36,967,000. Emerald Advisers LLC boosted its position in Karyopharm Therapeutics by 109.8% in the 4th quarter. Emerald Advisers LLC now owns 1,456,473 shares of the company’s stock valued at $13,647,000 after buying an additional 762,405 shares during the period. Emerald Mutual Fund Advisers Trust boosted its position in Karyopharm Therapeutics by 112.2% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,373,437 shares of the company’s stock valued at $12,869,000 after buying an additional 726,130 shares during the period. Candriam Luxembourg S.C.A. boosted its position in Karyopharm Therapeutics by 65.1% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,792,544 shares of the company’s stock valued at $16,795,000 after buying an additional 707,044 shares during the period. Finally, FMR LLC boosted its position in Karyopharm Therapeutics by 51.5% in the 4th quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after buying an additional 637,357 shares during the period. 84.48% of the stock is owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Read More: How to calculate compound interest
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.